An Effective Concentration of 5-Aza-CdR to Induce Cell Death and Apoptosis in Human Pancreatic Cancer Cell Line through Reactivating RASSF1A and Up-Regulation of Bax Genes

Mehdi Nikbakht Dastjerdi1, PhD; Asaad Azarnezhad2, PhD; Batool Hashemibeni3, PhD; Mansour Salehi4, PhD; Mohammad Kazemi4, PhD; Zahra Babazadeh1,5, PhD
1Department of Anatomical Sciences, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; 2Cellular and Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran; 3Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; 4Department of Molecular Biology, Isfahan University of Medical Science, Iran; 5Department of Anatomical Sciences, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran

Correspondence: Zahra Babazadeh, PhD; Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran Tel: +98 111 2192033 Fax: +98 111 2199936 Email: zbabazadeh@gmail.com Received: 22 January 2017 Revised: 25 February 2017 Accepted: 9 April 2017

Abstract

Background: Promoter hyper-methylation of tumor suppressor genes is a common event that occurs in cancer. As methylation is a reversible modification, agents capable of reversing an abnormal methylation status should help to combat cancer. 5-Aza-CdR is a DNA methyl-transferase inhibitor. The present study aimed to evaluate the effect of 5-Aza-CdR on the proliferation of human pancreatic cancer cell line (PANC-1) and the expression of RASSF1A and Bax genes.

Methods: PANC-1 cells were cultured and treated with 5 and 10 µM/L of 5-Aza-CdR for 24, 48, 72, and 96 hours and the percentages of cell viability and apoptosis were measured by MTT and flow cytometry. RASSF1A gene promoter methylation was assessed by methyl-specific primer-PCR (MSP-PCR) and the expression of RASSF1A and Bax genes was measured using quantitative real-time PCR (qPCR). All quantitative data are presented as mean±SD (standard deviation). The one-way analysis of variance (ANOVA) with the LSD post hoc test was performed for statistical analysis using the SPSS software package, version 16.0.

Results: 3-[4,5-dimethythiaziazol-2yl]-2,5-diphenyl tetrazoliumbr omide (MTT) assay revealed that 5-Aza-CdR significantly inhibit the growth and proliferation of PANC-1. The flow cytometry results showed over 40% and 70% of early and late apoptotic cells after treatment with 5 and 10 µm/L of 5-Aza-CdR, respectively. MSP-PCR data indicated that the treatment of cells with 10 µm/L 5-Aza-CdR resulted in partial demethylation of RASSF1A gene promoter. qPCR results showed significant re-expression of RASSF1A and up-regulation of Bax genes after 96 hours treatment of cells with 10 µm/L 5-Aza-CdR versus control cells (P<0.01).

Conclusion: The result demonstrated that 5 and 10 µM of 5-Aza-CdR can limit the proliferation of human pancreatic cancer cell line (PANC-1) through epigenetic reactivation of RASSF1A and consequently up-regulation of Bax in a time- and dose-dependent manner.

Keywords ● Decitabine ● Pancreatic Neoplasms ● DNA modification methylases ● Methylation

Introduction

Pancreatic cancer (PC) is known as “silent killer” because there are no clear symptoms in the early stage of the disease. Specific
symptoms usually develop until the later stages of the disease. For this reason, pancreatic cancer is the eighth and the ninth leading causes of cancer-related death in men and women, respectively.1-3 About 5-10% of patients with pancreatic cancer have almost a family history and inherited mutations in few genes, including BRCA2, p16/CDKN2A, PRSS1, STK11, hMLH1, and FANCC that account for less than 20% of familial clustering.4 However, similar to most other cancers, PC is a multifactorial disease that occurs in a multi-stage process in which genetic and epigenetic factors control its development.

Methylation is the major epigenetic regulation of genes in which a methyl residue is added on cytosine in CpG dinucleotide catalyzed by DNA methyltransferases (DNMTs). Although the CpG islands are concentrated mostly in the gene promoter, approximately 5% of these promoters are methylated. However, this figure is far higher in cancer and changes in DNA methylation is one of the cancer hallmarks.5 On the other hand, the alteration of DNA methylation has been reported to be related to up-regulation of DNMTs and whole genome methyl analysis have shown hypomethylation and hypermethylation in pancreatic cancer.6

Different mechanisms, including point mutation, gene deletion, and hypermethylation are involved in the inactivation of tumor suppressor genes (TSGs). Promoter hypermethylatation of Ras association domain family 1A (RASSF1A) gene is one of the frequent events reported in a large variety of cancers. RASSF1A is known as a significant tumor suppressor and controls the growth of cells through the inhibition of RAS pathway.7 Lack of RASSF1A expression has been reported in different tumors.8,9 It also induces cell cycle arrest, apoptosis, genomic, and microtubule instability and its ectopic expression in different cell lines of cancers has been indicated that suppresses the tumor growth.10-14 Apoptosis is a physiological event that is a critical homeostasis regulation in normal tissue.12 Several bio-molecules are involved in this process, including BCL-2 family. Bax gene is the first pro-apoptotic member of BCL-2 family, which acts as the heart of intrinsic apoptosis pathway. Bax is inserted tightly within the outer mitochondrial membrane and involved in promoting death during apoptosis. Bax and/or Bak proteins assemble and induces penetration in the outer membrane of mitochondria to release apoptotic components such as cytochrome C.15 The ability of cells to escape from apoptosis allows tumors to develop metastasis and chemotherapy resistance. Therefore, loss of function of key genes such as RASSF1A through methylation can lead to loss of vital function of cells including apoptosis and cell growth control. Bax expression, as a pro-apoptotic biomarker, was measured for confirming the effect of 5-AZA-CdR on apoptosis through epigenetic reactivation of RASSF1A.

DNA methylation and histone modification are the two major characteristics of epigenetic events, nevertheless, they are reversible.16 Hence, using agents with the capability of epigenetic reversion can be used to re-express the important gene silenced via methylation. 5-Aza-2'-deoxycytidine (5-AZA-CdR, decitabine) is a demethylating agent that its pharmacological effects were first reported for the treatment of leukemia in 1968.17 However, approving 5-AZA-CdR potential as a therapeutic agent for cancer treatment took a long time.18,19 On the other hand, there are limited reports on the clinical activity of 5-AZA-CdR on solid tumors.17 5-Aza-CdR makes the transcriptional activation by promoter demethylation and DNMT inactivation.20 Therefore, we encouraged to design the current study to examine the sufficient dose of 5-Aza-cdr on PANC-1, epigenetic reversion of RASSF1A, and up-regulation of Bax. In doing so, appropriated time and concentration of 5-Aza-cdr as an epigenetic treatment could be introduced to control cancers and improve its prognosis.

Materials and Methods

Cell Line and Cell Culture

PANC-1 was provided from the national cell bank, Pasteur Institute of Iran (Tehran, Iran). The cells were cultured in T25 culture flask containing high glucose DMEM (Sigma, USA) supplemented with 10% fetal bovine serum (FBS) (Sigma, USA) and 1% penicillin-streptomycin (Sigma, USA) at 37 °C in a humidified atmosphere containing 5% CO2. When cells got to their logarithmic phase of growth (80% confluent cells), 10^5 cells were transferred to 24-well culture plates. Drug treatment was performed 24 hours after cell seeding.12 5-Aza-CdR Treatment

A stock solution of 5-Aza-CdR (50 mM) (Sigma, USA) was dissolved in DMSO and stored at -80 °C. The stock was diluted in cell culture media at different concentrations and IC50 was determined. Each culture was treated with different experimental dosages for 24, 48, 72, and 96 hours and treated cells were then harvested for further analysis. Culture without intervention with 5-Aza-CdR was considered as the control group.
5-Aza-CdR-mediated apoptosis of PANC-1 cells

**MTT Assay**

MTT assay was carried out to determine the viability of treated PANC-1 cells by 5-Aza-CdR according to previously reported instruction.\(^{21}\) 5-Aza-CdR was dissolved in PBS at the final concentration of 5 mg/ml (82.5 µM). Then, the stock solution was added to the culture medium at a dilution of 1:10. The cells were incubated at 37 °C for 4 hours. In the next step, the medium was aspirated and 400 µl of DMSO was added to the extract. The cell viability rate was calculated as the percentage of MTT absorption by a microplate reader (Hiperion MPR 4, Germany) at the wavelength of 570 nm.

**DNA Extraction, Bisulfite Treatment, and Methylation Specific PCR (MSP)**

Initially, the isolation of genomic DNA was accomplished by PrimePrep™ Genomic DNA isolation kit (GeNet Bio, Korea) according to manufacturer’s instruction. Sodium bisulfate treatment of the extracted DNA was performed using the EpiTect Bisulfite kit (Qiagen, Germany) according to manufacturer’s instruction. Next, the PCR reactions were carried out in thermal cycler EP-Gradient PCR (Eppendorf, Germany) according to the previous study.\(^{11}\)

**Quantitative Real-Time Polymerase Chain Reaction (qPCR)**

Total RNA isolation from each cell group was performed by RNasy Mini kit (Qiagen, USA). RNA samples were treated with RNase-free DNase (Qiagen, USA) to eliminate any possible contamination with genomic DNA. RNA concentration was measured using BioPhotometer (Eppendorf, Germany). 5 µl of total RNA (200 ng/µl) was reverse-transcribed to cDNA by RevertAid™ kit (Fermentas, EU) according to the manufacturer’s instruction. qPCR was carried out using the Maxima SYBR Green/ROX qPCR master mix kit (Fermentas, EU). The primers for amplifying the target regions were designed using AlleleID software (Primer Biosoft, USA) with the following sequences: RASSF1A (forward 5'-TCATCTGGGGCAGTCGTG-3', reverse 5'-CGTTCGTGTCCCGCTCC-3'), Bax (forward 5'-GACCAGCATGACAGATTTCTACCA-3', reverse 5'-AACTGAGACTAAAGGAAGATG-3'), and the reference gene ACTB (forward 5'-GTTGTCGACGACGCG-3', reverse 5'-GCACTGACACTCAAGGTCA3'). qPCR reactions were carried out in StepOnePlus™ quantitative real-time PCR detection system (Applied Biosystems, USA). The PCR amplification conditions consisted of 10 minutes at 95 °C followed by 40 cycles of denaturation at 95 °C for 15 seconds and annealing and extension for 1 minute at 60 °C. The gene expression ratios were calculated by the 2^{-\Delta\Delta Ct} method. These experiments were carried out in triplicates and the mean Ct put into expression analysis.

**Flow Cytometric Analysis**

The percentage of the apoptotic cell was evaluated by Annexin-V-FLUOS staining kit (Roche). About 10^6 cells of each sample were washed in PBS and re-suspended in 100 µl of Annexin-V-FLUOS labeling solution. Cells were then incubated at room temperature for 10-15 minutes. Finally, the apoptotic cells were counted by FACSscan flow cytometry (Becton Dickinson, Heidelberg, Germany). Annexin-V-FITC can discriminate between apoptotic and necrotic cells. In apoptotic cells, the phospholipid phosphatidylserine is exposed on the outer surface of plasmalemma, leading to binding of Annexin-V and apoptotic cells stain green. However, necrotic cells take up propidium iodide and stain orange/green. These experiments were performed in triplicates intermittently.

**Statistical Analysis**

All the quantitative data are presented as mean±SD (standard deviation). The one-way analysis of variance (ANOVA) with the LSD post hoc test was performed to determine statistical significance among different groups using the SPSS software package, version 16.0. P<0.05 was accepted as a significant level.

**Results**

**MTT Assay**

Dose-response curves for 5-Aza-CdR treatment were designed based on MTT assay results to determine IC\(_{50}\). Different concentrations of 5-Aza-CdR were tested during 24, 48, 72, 96 hours. No significant anti-cancer effect was observed during the first three days, but cell viability was significantly decreased after 4 days of treatment (96 h). The survival rate of cells after 96 hours of treatment with concentrations of 5 and 10 µM was 55% and 45%, respectively, and determined as IC\(_{50}\) (table 1). Morphological change of treated cells is illustrated in figure 1.

**MSP-PCR**

The findings revealed that treatment with 10 µM 5-Aza-CdR for 4 days induced partial demethylation of RASSF1A gene in PANC-1 cell line.\(^{11}\)

**Real-Time PCR**

The result showed no significant re-expression and up-regulation of RASSF1A and Bax after
treatment of cells with 5 µM (P=0.087), while RASSF1A re-expression (P=0.034) and Bax up-regulation (P=0.042) were significant after treatment with 10 µM of 5-Aza-CdR compared to the untreated group (figure 2).

Flow Cytometry
An apoptosis assessment was done using the PI/Annexin-V dot plots as follow: Annexin-V and PI negative cells were known as normal and undamaged cells, apoptotic cells were those stained with annexin-V but negative for PI, and necrotic cells were those with both annexin-V and PI positive. Compared to the control (73%), the percentage of PANC-1 cell viability reduced to 54% and 28% in the presence of 5 µmol and 10 µmol after 96 hours of treatment, respectively (figure 3).

Discussion
In the present study, the time- and dose-dependent epigenetic effects of 5-Aza-CdR on PANC-1 were evaluated. Our results showed that 5-Aza-CdR has an inhibitory effect on PANC-1 growth after 4 days through the re-expression of RASSF1A and up-regulation of Bax, as the key players involved in apoptosis. It was observed that 10 µM of 5-Aza-CdR was a more effective concentration on PANC-1.

Table 1: The percentages of PANC-1 cell viability after treatment with 5-Aza-CdR in different dosages (1, 5, 10, 15, 20, 25, and 30 µM) and at different times (24, 48, 72, and 96 hours)

| Cell viability after 24 h treatment (%) | Cell viability after 48 h treatment (%) | Cell viability after 72 h treatment (%) | Cell viability after 96 h treatment (%) |
|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| 5-Aza-CdR (1 µM)                       | 100                                    | 100                                    | 100                                    |
| 5-Aza-CdR (5 µM)                       | 100                                    | 96                                     | 92                                     |
| 5-Aza-CdR (10 µM)                      | 98                                     | 84                                     | 78                                     |
| 5-Aza-CdR (15 µM)                      | 95                                     | 80                                     | 74                                     |
| 5-Aza-CdR (20 µM)                      | 95                                     | 78                                     | 75                                     |
| 5-Aza-CdR (25 µM)                      | 86                                     | 75                                     | 72                                     |
| 5-Aza-CdR (30 µM)                      | 88                                     | 73                                     | 70                                     |

Figure 1: The morphologic view of PANC-1 after treatment with 5 and 10 µm of 5-Aza-CdR (×100). Clearly, the percentage of survived cells has significantly decreased after 96 hours of treatment with 10 µm of 5-Aza-CdR.

Figure 2: 5-Aza-CdR treatment in PANC-1 (5 and 10 µM for 96 h). 10 µm of 5-Aza-CdR epigenetically induced re-expression of RASSF1A (P=0.042) and subsequently up-regulation of Bax genes (P=0.034). However, in a concentration of 5 µm, the expression ratio of these genes was not significantly different in comparison with controls (P=0.784).

DNA methylation is a major part of epigenetic events that has a significant role in the cellular process, including genomic imprinting, tissue-specific gene expression, chromosomal inactivation, and tumor specific gene expression. This event is catalyzed and maintained by DNMTs enzymes. Inactivation of TSGs is closely related to hypermethylation of CpG islands of the promoter region. On the other hand, the overexpression of DNMTs is a reason for gene silencing and cancer induction. Fortunately, epigenetic events are reversible through DNMTs inhibition, hence, epigenetic reversion has attracted attention in drug discovery in cancer treatment studies. 5-Aza-CdR activity in inhibition of DNMTs has previously been reported and its therapeutic use in low-dose was encouraged in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). However, the evaluation of its effects on solid
tumors has been limited which requires more investigations.\textsuperscript{25,26}

An abnormal pattern of DNA methylation is observed in human neoplasia, although the promoter region of tumor suppressor genes in normal cells is unmethylated.\textsuperscript{27} Therefore, any alterations of gene expression after 5-Aza-CdR treatment in normal cells are unrelated to 5-Aza-CdR DNMT inhibitory effects.\textsuperscript{28} On the other hand, Qiu demonstrated that 5-Aza-CdR did not show any synergistic effect on the growth inhibition of normal fibroblast in combination with irradiation, while radiotherapy alone induced normal cell necrosis.\textsuperscript{29} Furthermore, Fandy explained that 5-Aza-CdR incorporated only into DNA whereas 5-AC incorporates in RNA, interferes with protein translation, and induces specific cytotoxicity. This character of 5-Aza-CdR has made it more efficient on tumor cells and tissue in current clinical trials.\textsuperscript{27}

Many studies have demonstrated that RASSF1A is expressed in all normal tissues, while none or low expression of this gene has been reported in many cancers, including the lung, pancreas, liver, and biliary tract cancers.\textsuperscript{30,31} Some studies have shown that RASSF1A does not act through enzymatic activity, but functions as an underlying factor for other complex signaling pathways. It has two promoters; the shorter promoter has a length of 737 bp containing about 85 C and G dinucleotides and found in RASSF1A, RASSF1D, RASSF1E, RASSF1F, and RASSF1G genes. The longer promoter consists of 1364 bp and contains 139 CpG that acts as the promoter of RASSF1C and RASSF1B genes. Among this family, A and C isoforms have been biologically analyzed and little data are available about B, D, E, F, G, and H isoforms.\textsuperscript{32}

It is reported that RASSF1A regulates the G1-S phase of cell cycle by controlling the level of cyclin D1. Inhibition of JNK pathway has been found to be the reason for this regulation.\textsuperscript{33} It is also believed that RASSF1 family is a member of pro-apoptosis proteins and activates apoptosis through a variety of intracellular pathways.\textsuperscript{34} In the current study, the demethylation effect and molecular mechanisms of a DNMT enzyme inhibitor, known as 5-Aza-CdR, on the PANC-1 cell line showed the same results as Pfeifer; that concentrations of 5 and 10 µM were more effective.\textsuperscript{35}

Treatment with 5-Aza-CdR during the initial three days did not induce cell death while cell growth inhibition in comparison with the control group was significant on the fourth day after treatment (figure 3). This finding was partially consistent with the results reported by Stresemann et al.\textsuperscript{36} Epigenetic reversion has previously been reported in the first and second days of treatment; however, the time dependency of 5-Aza-CdR has not been mentioned.\textsuperscript{37-39} Therefore, 5-Aza-CdR probably needs more incubation (i.e. at least more than three days) to be an effective epigenetic therapy.

Our results also showed that the treatment of PNAC-1 cells with 5-Aza-CdR leads to partial
demethylation of RASSF1A gene promoter. After treatment with 5-Aza-CdR, unmethylated bands were observed in the MSP assay. The results of MSP were confirmed by measuring the gene expression ratio of RASSF1A before and after treatment by qPCR in which significantly increased expression value was seen after treatment (figure 2). This is in accordance with the studies conducted by Zuo, Agathangglous, and Shen.\(^{23,32,37}\) Therefore, RASSF1A promoter hypermethylation seems to be an important occurrence in the pathogenesis of cancer (particularly pancreatic cancer) and its targeted epigenetic therapy can open a promising window to cancer treatment.\(^{38}\)

As mentioned, RASSF1A gene has several functions and its inactivation is expected to affect various aspects of tumor biology. Vos reported that RASSF family proteins probably act as mediators for inducing some Ras-related growth inhibition and apoptosis. Through MOAP-1, RASSF1A activates Bcl-2 family proteins, including Bax and consequently intrinsic pathway of apoptosis.\(^{39}\) In the present study, the correlation of RASSF1A re-expression by 5-Aza-CdR with cell apoptosis was investigated by measuring Bax gene expression ratio. Consistent with previous studies,\(^{39}\) Bax gene expression was not significant (P=0.087) in 5 µM concentration, whereas its expression increased significantly (P=0.042) in 10 µM concentration compared with the control group (figure 2). Conversely, we have previously demonstrated the apoptotic effect of disulfiram (DSF) and Bax up-regulation after 24 hours of treatment without RASSF1A re-expression.\(^{12}\) Furthermore, the flow cytometry data confirmed the activation of apoptosis pathway in treated cells and cell viability had a decreasing trend. The percentage of viable cells in untreated, 5 µM treated, and 10 µm treated groups was 73%, 54%, and 28%, respectively (figure 3). However, it would have been better to investigate the expression of RASSF1A and Bax at the protein level before and after treatment with 5-Aza-CdR. In addition, detailed tracking of signaling pathway activated by the reactivated RASSF1A could guide us to a better understanding of the molecular profile of the survived cells.

**Conclusion**

Taken together, 5-Aza-CdR was found to have a partial demethylation effect and epigenetically reverses the expression of silenced RASSAF1A in PNAC-1 cell line. It was also found that the epigenetic reversion potential of 5-Aza-CdR is time- and dose-depending and did not occur before day 4. Furthermore, the result showed a correlation between Bax up-regulation and RASSF1A re-expression. Discovering agents with demethylation effect could help cancer treatment.

**Acknowledgment**

The authors greatly appreciate the assistance of Dr. Ali Valiani, Dr. Mohammad Reza Salahshoor, Dr. Fatemeh Sadat Mostafavi, and Mrs. Maryam Aliatkbari; without their contribution, this study could not have been performed. The research was supported by a grant (number 390569) from Isfahan University of Medical Sciences (Isfahan, Iran).

**Conflict of Interest:** None declared.

**References**

1. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). 2008;10:58-62. doi: 10.1080/13651820801883148. PubMed PMID: 18695761; PubMed Central PMCID: PMCPMC2504856.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29. doi: 10.3322/caac.20138. PubMed PMID: 22237781.
3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2015;65:87-108. doi: 10.3322/caac.21262. PubMed PMID: 25651787.
4. Brune K, Hong SM, Li A, Yachida S, Abe T, Griffith M, et al. Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev. 2008;17:3536-42. doi: 10.1158/1055-9965.EPI-08-0630. PubMed PMID: 19064568; PubMed Central PMCID: PMCPMC2664523.
5. Weber M. Profiles of DNA methylation in normal and cancer cells. Med Sci (Paris). 2008;24:731-4. doi: 10.1051/medsci/20082489731. PubMed PMID: 18789220.
6. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A, et al. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol. 2009;3:425-38. doi: 10.1016/j.molonc.2009.03.004. PubMed PMID: 19497796; PubMed Central PMCID: PMCPMC5527529.
7. Amato E, Barbi S, Fassan M, Luchini C, Vicentini C, Brunelli M, et al. RASSF1
tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes. BMC Cancer. 2016;16:11. doi: 10.1186/s12885-016-2048-0. PubMed PMID: 26754001; PubMed Central PMCID: PMC4710004.

8. Wang Y, Xu M, Di ZH, Zhang J, Mao XQ, Sun HB. Regulation of demethylation and re-expression of RASSF1A gene in hepatocellular carcinoma cell lines treated with NCTD in vitro. J Cancer Res Ther. 2015;11:818-22. doi: 10.4103/0973-1482.146126. PubMed PMID: 26881524.

9. Grawenda AM, O’Neill E. Clinical utility of RASSF1A methylation in human malignancies. Br J Cancer. 2015;113:372-81. doi: 10.1038/bjc.2015.221. PubMed PMID: 26158424; PubMed Central PMCID: PMCPMC4522630.

10. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci. 2007;120:3163-72. doi: 10.1242/jcs.010389. PubMed PMID: 17878233.

11. Dastjerdi MN, Babazadeh Z, Salehi M, Hashemibeni B, Kazemi M. Comparison of the anti-cancer effect of Disulfiram and 5-Aza-CdR on pancreatic cancer cell line PANC-1. Adv Biomed Res. 2014;3:156. doi: 10.4103/2277-9175.137866. PubMed PMID: 25221759; PubMed Central PMCID: PMC4162084.

12. Dastjerdi MN, Babazadeh Z, Rabbani M, Gharagozloo M, Esmaeili A, Narimani M. Effects of disulfiram on apoptosis in PANC-1 human pancreatic cancer cell line. Res Pharm Sci. 2014;9:287-94. PubMed PMID: 25657800; PubMed Central PMCID: PMC4314877.

13. Donninger H, Clark JA, Monaghan MK, Schmidt ML, Vos M, Clark GJ. Cell cycle restriction is more important than apoptosis induction for RASSF1A protein tumor suppression. J Biol Chem. 2014;289:31287-95. doi: 10.1074/jbc.M114.609537. PubMed PMID: 25225292; PubMed Central PMCID: PMC4223329.

14. Ghavifekr Fakhr M, Farshdousti Hagh M, Shanehbandi B, Baradaran B. DNA methylation pattern as important epigenetic criterion in cancer. Genet Res Int. 2013;2013:317569. doi: 10.1155/2013/317569. PubMed PMID: 24455281; PubMed Central PMCID: PMC3884803.

15. Li JH, Xiao X, Zhang YN, Wang YM, Feng LM, Wu YM, et al. MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecol Oncol. 2011;120:145-51. doi: 10.1016/j.ygyno.2010.09.009. PubMed PMID: 20947150.

16. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009;10:295-304. doi: 10.1038/nrg2540. PubMed PMID: 19308066.

17. Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics. 2013;5:3. doi: 10.1186/1868-7083-5-3. PubMed PMID: 23369223; PubMed Central PMCID: PMCPMC3570332.

18. de Vos D, van Overveld W. Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol. 2005;84:3-8. doi: 10.1007/s00277-005-0008-x. PubMed PMID: 16220311.

19. Phan NL, Trinh NV, Pham PV. Low concentrations of 5-aza-2'-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression. Onco Targets Ther. 2016;9:49-59. doi: 10.2147/OTT.S96291. PubMed PMID: 26730203; PubMed Central PMCID: PMCPMC4694670.

20. Jiao Y, Hannafon BN, Ding WQ. Disulfiram’s Anticancer Activity: Evidence and Mechanisms. Anticancer Agents Med Chem. 2016;16:1378-84. PubMed PMID: 27141876.

21. Moloudi K, Neshasteriz A, Hosseini A, Eyvazzadeh N, Shomali M, Eynali S, et al. Synergistic Effects of Arsenic Trioxide and Radiation: Triggering the Intrinsic Pathway of Apoptosis. Iran Biomed J. 2017;21:330-7. PubMed PMID: 28459147; PubMed Central PMCID: PMCPMC5548965.

22. Lim DH, Maher ER. DNA methylation: a form of epigenetic control of gene expression. Obstetrician and Gynaecologist. 2010;12:37-42. doi: 10.1576/toag.12.1.037.27556.

23. Zuo S, Chen Y, Xu L, Tang Q, Zou S. Re-expression of RASSF1A by 5-Aza-CdR induced demethylation of the promoter region in human biliary tract carcinoma cells. J Huazhong Univ Sci Technol Med Sci. 2007;27:281-4. doi: 10.1007/s11596-007-0316-6. PubMed PMID: 17641842.

24. Brueckner B, Kuck D, Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J. 2007;13:17-22. doi: 10.1097/PPO.0b013e31803c7245. PubMed PMID: 17464242.
25. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol. 2005;25:4727-41. doi: 10.1128/MCB.25.11.4727-4741.2005. PubMed PMID: 15899874; PubMed Central PMCID: PMC51140649.

26. Schmelz K, Wagner M, Dorken B, Tamm I. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer. 2005;114:683-95. doi: 10.1002/ijc.20797. PubMed PMID: 15609309.

27. Fandy TE. Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr Med Chem. 2009;16:2075-85. PubMed PMID: 19519382.

28. Karpf AR, Lasek AW, Hanks AN, Grossman D, Jones DA. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol. 2004;65:18-27. doi: 10.1124/mol.65.1.18. PubMed PMID: 14722233.

29. Qiu H, Yashiro M, Shinto O, Matsuzaki T, Hirakawa K. DNA methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of gastric cancer cells. Cancer Sci. 2009;10:181-8. doi: 10.1111/j.1349-7006.2008.01004.x. PubMed PMID: 19037991.

30. Yang B, House MG, Guo M, Herman JG, Clark DP. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol. 2005;18:412-20. doi: 10.1038/modpathol.3800287. PubMed PMID: 15467712.

31. Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers. 2007;23:73-87. PubMed PMID: 17325427; PubMed Central PMCID: PMC53850810.

32. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005;65:3497-508. doi: 10.1158/0008-5472.CAN-04-4088. PubMed PMID: 15867337.

33. Whang YM, Kim YH, Kim JS, Yoo YD. RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression. Cancer Res. 2005;65:3682-90. doi: 10.1158/0008-5472.CAN-04-2792. PubMed PMID: 15867363.

34. Law J, Yu VC, Baksh S. Modulator of Apoptosis 1: A Highly Regulated RASSF1A-Interacting BH3-Like Protein. Mol Biol Int. 2012;2012:536802. doi: 10.1155/2012/536802. PubMed PMID: 22745908; PubMed Central PMCID: PMC3382356.

35. Pfeifer GP, Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc). 2005;70:576-83. PubMed PMID: 15948711.

36. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 2006;66:2794-800. doi: 10.1158/0008-5472.CAN-05-2821. PubMed PMID: 16510601.

37. Shen WJ, Dai DQ, Teng Y, Liu HB. Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB. World J Gastroenterol. 2008;14:595-600. PubMed PMID: 18203293; PubMed Central PMCID: PMC2681152.

38. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008;28:752-71. doi: 10.1128/MCB.01799-07. PubMed PMID: 17991895; PubMed Central PMCID: PMC2223421.

39. Vos MD, Dallol A, Eckfeld K, Allen NP, Donninger H, Hesson LB, et al. The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem. 2006;281:4557-63. doi: 10.1074/jbc.M512128200. PubMed PMID: 16344548.